RT Journal Article
SR Electronic
T1 Psychosis spectrum symptoms among individuals with schizophrenia-associated copy number variants and evidence of cerebellar correlates of symptom severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.03.03.22271848
DO 10.1101/2022.03.03.22271848
A1 Sefik, Esra
A1 Guest, Ryan M.
A1 Aberizk, Katrina
A1 Espana, Roberto
A1 Goines, Katrina
A1 Novacek, Derek M.
A1 Murphy, Melissa M.
A1 Goldman-Yassen, Adam E.
A1 Cubells, Joseph F.
A1 Ousley, Opal
A1 Li, Longchuan
A1 Shultz, Sarah
A1 Walker, Elaine F.
A1 Mulle, Jennifer G.
YR 2023
UL http://medrxiv.org/content/early/2023/09/22/2022.03.03.22271848.abstract
AB The 3q29 deletion (3q29Del) is a copy number variant (CNV) with one of the highest effect sizes for psychosis- risk (>40-fold). Systematic research offers promising avenues for elucidating mechanism; however, compared to CNVs like 22q11.2Del, 3q29Del remains understudied. Emerging findings indicate that posterior fossa abnormalities are common among carriers, but their clinical relevance is unclear. Here, we report the first in- depth evaluation of psychotic symptoms in participants with 3q29Del (N=23), using the Structured Interview for Psychosis-Risk Syndromes, and compare this profile to 22q11.2Del (N=31) and healthy controls (N=279). By neuroimaging, we also explore correlations between psychotic symptoms and posterior fossa abnormalities in 3q29Del. Cumulatively, 48% of the 3q29Del sample exhibited a psychotic disorder or attenuated positive symptoms, with a subset meeting criteria for clinical high-risk. 3q29Del had more severe ratings than controls on all domains and only exhibited less severe ratings than 22q11.2Del in negative symptoms, with select sex differences. An inverse relationship was identified between positive symptoms and cerebellar cortex volume in 3q29Del, documenting the first clinically-relevant neuroanatomical connection in this syndrome. Our findings characterize the profile of psychotic symptoms in the largest 3q29Del sample reported to date, contrast with another high-impact CNV, and highlight cerebellar involvement in elevated psychosis-risk.HighlightsThe rare copy number variants (CNVs) 3q29Del and 22q11.2Del confer the largest known effect sizes for schizophrenia susceptibility.While 22q11.2Del’s link with psychosis has been extensively studied, in-depth characterization of psychotic symptoms associated with 3q29Del is lacking.This study fills this gap and provides the first phenotypic comparison of psychotic symptom profiles in carriers of these CNVs, and healthy controls.Additionally, we uncover a novel genetic association between 3q29Del, psychotic symptoms, and cerebellar cortex development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge the 3q29Del study population, their families and all project members. We thank the Marcus Autism Center for providing clinical assessment resources. We thank all NAPLS2 PIs for their contributions to the HC dataset. Funding for this work was provided in part by National Institute of Mental Health grants R01MH110701, R01MH118534, U01MH081988 and grants by the Robert W. Woodruff Fund and the Predictive Health Initiative of Emory University. The authors have no competing financial interests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board of Emory University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes